Evidence map›Paper›PMID 39991668›Full record

ArticleJournal of inflammation research2025

SIL-TAL1-Positive Adult T-ALL with t(11;14)(p15;q11.2): A Rare Case Report Highlighting Prognostic Challenges and Treatment Implications.

Siyu Chen, Shengwang Wu, Nan Li, Xing Qiang, Yongjie Tang, Yimei Feng, Cheng Zhang, Xiangui Peng, Shuiqing Liu, Xi Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Siyu Chen *Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Shengwang Wu *Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Nan LiMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Xing QiangMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Yongjie TangMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Yimei FengMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.ORCID 0000-0003-1904-791X
Cheng ZhangMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Xiangui PengMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.
Shuiqing LiuMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.ORCID 0009-0000-1055-3221
Xi ZhangMedical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) with coexisting SIL-TAL1 fusion and t(11;14)(p15;q11.2) is exceedingly rare. There are limited data on the clinical course and outcomes of such patients. We report a case of a 19-year-old male presenting with aggressive T-ALL harboring these abnormalities, along with NOTCH1 and PTEN mutations. SIL-TAL1 positivity is associated with poor prognosis in T-ALL. Despite achieving remission with intensive chemotherapy, the patient experienced rapid relapse and poor overall survival, reflecting the ineffectiveness of conventional treatments. The findings highlight the synergistic role of SIL-TAL1 and t(11;14) in disease progression and underscore the urgent need for targeted therapies and immunotherapies to improve outcomes in such high-risk cases.

Indexed as

NOTCH1PTENSIL-TAL1t(11,14)(p15,q11.2)targeted therapyT-cell acute lymphoblastic leukemia

Identifiers

PMID39991668
PMCPMC11844270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.